雷替曲塞联合伊立替康治疗晚期大肠癌的的疗效观察.docVIP

雷替曲塞联合伊立替康治疗晚期大肠癌的的疗效观察 　　[摘要] 目的 探讨雷替曲塞联合伊立替康二线治疗大肠癌的疗效及安全性评价。 方法 选择2011年6月～2014年12月间的78例经FOLFOX方案一线化疗失败的复发性或转移性大肠癌患者，随机分为FOLFIRI组和雷替曲塞联合伊立替康组。FOLFIRI组38例，予FOLFIRI方案化疗；雷替曲塞联合伊立替康组40例，予雷替曲塞联合伊立替康化疗。两组均至少治疗2个周期，观察疗效、不良反应，并随访观察中位无疾病进展生存期（MPFS）、1年生存率。结果 雷替曲塞联合伊立替康组的有效率42.50%，明显高于FOLFIRI组（13.16%），差异具有统计学意义（P0.05）；两组胃肠道不适、粒细胞减少、腹泻等不良反应差异无统计学意义（P0.05）。 结论 雷替曲塞联合伊立替康二线治疗晚期大肠癌疗效肯定，安全性好，值得临床推广。 　　[关键词] 伊立替康；雷替曲塞；晚期大肠癌；二线治疗 　　[中图分类号] R735.3 [文献标识码] B [文章编号] 1673-9701（2015）34-0071-03 　　Effect of irinotecan combined with raltitrexed as second-line chemotherapy in the treatment of advanced colorectal cancer 　　LIU Jun WEN Fugang LI Bin 　　Eight Ward， Department of Medical Oncology， Anshan Tumor Hospital in Liaoning Province， Anshan 114031， China 　　[Abstract] Objective To evaluate the efficacy and toxicity of irinotecan combined with raltitrexed as second-line chemotherapy in the treatment of advanced colorectal cancer. Methods A total of 78 patients with advanced colorectal cancer who had received FOLFOX first-line therapy but had relapsed or progressed from June 2011 to December 2014 were selected. All patients were randomly divided into FOLFIRI group （n=38） and irinotecan combined with raltitrexed group（n=40）. The patients in FOLFIRI group were treated with FOLFIRI chemotherapy， and the patients in irinotecan combined with raltitrexed group were given irinotecan and raltitrexed. All patients were given two cycles of chemotherapy at least. Then the efficacy， toxicity， median progression-free survival （MPFS） and one year survival rate were evaluated. Results The effective rate in irinotecan combined with raltitrexed group was 42.50%， significantly higher than that of 13.16% in the FOLFIRI group， and the difference was statistically significant（P0.05）. The toxicities included gastrointestinal reaction， neutropenia and diarrhea had no significant difference between two groups（P0.05）. Conclusion Irinotecan combine with raltitrexed as second-line chemotherapy in treatment of a